Trial Profile
Assess the consistency of the immunogenicity of a GlaxoSmithKline Biologicals' pandemic influenza vaccine (GSK1562902A) in adults aged between 18 and 60 years.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Jun 2023
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary) ; AS03A
- Indications Influenza A virus H5N1 subtype
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
- 10 Nov 2011 Actual end date (June 2008) added as reported by ClinicalTrials.gov
- 29 Sep 2011 NCT00449670 reports patients number as 1181.
- 27 Oct 2008 Actual end date changed from Jun 2008 to Jul 2007 as reported by Clinicaltrials.gov.